This one-day program at the Naomi Berrie Diabetes Center at Columbia University is designed for research scientists, clinicians and students with an interest in the latest insights with regard to the biological basis for medical complications that affect patients with diabetes, and novel therapeutic approaches that may mitigate these pathologies.

Specifically, while persistent hyperglycemia may cause microvascular (retinopathy, nephropathy and neuropathy) disease, knowledge of downstream molecular effectors is likely to enable more effective therapies to prevent significant morbidity. Further, a direct link between excess glucose per se and cardiovascular and liver disease is far less certain, implying that other comorbid metabolic abnormalities such as hyperinsulinemia/insulin resistance and dyslipidemia may contribute to these associated disorders.

At the conclusion of this activity, participants will be better able to:
•Recognize the major microvascular and macrovascular complications associated with diabetes, and associated current treatment paradigms.
•Specify some of the molecular mechanisms linking these complications to diabetes.
•Discuss novel potential technologies for prevention of diabetes-related complications.